

United Nations to be the first speaker at the historic Conference on Disarmament and Development. That was a recognition of Canada's continued leadership in seeing that the world pursues an intelligent course of nuclear disarmament and channels those moneys into developmental issues, which will solidify the problems and priorities and strengthen the Third World developments.

The Acting Speaker (Mr. Paproski): The Hon. Member will have seven minutes left in his debate next time this motion comes up on Private Members' Business. The hour provided for the consideration of Private Members' Business has now expired.

Pursuant to Standing Order 36(2) the order is dropped to the bottom of the list of the order of precedence on the Order Paper.

GOVERNMENT ORDERS

[English]

PATENT ACT

MEASURE TO AMEND—CONSIDERATION OF SENATE AMENDMENTS

The House resumed from Friday, August 28, consideration of the motion of Mr. Andre:

That a Message be sent to the Senate to acquaint their Honours that this House agrees with amendment 10(a) made by the Senate to Bill C-22, an Act to amend the Patent Act and provide for certain matters in relation thereto, but disagrees with all other amendments except amendments 1(c) and 8, because this House believes that amendments 1(a) and (b), 2(a) and (b), 3, 4(a) and (b), 5(a) and (b), 6, 7(a) and (b), 9 and 10(b) and (c) are in contradiction to the principles of the Bill which will increase intellectual property protection, increase research and development in Canada, create new high-technology jobs, improve the health care of Canadians, and protect consumers from higher drug prices. More specifically:

Amendments 1(a) and (b) delete the definitions of "Board" and "patentee". These definitions are necessary to support the powers of the Patented Medicine Prices Review Board, which is required to protect consumers.

Amendments 2(a) and (b) reduce Canada's export potential and fine chemical manufacturing.

Amendments 3, 4(a) and (b), reduce the periods of market exclusivity, thus eliminating the incentive for increased research and development in Canada.

Amendment 5(a) reduces the period of market exclusivity and export potential, thus reducing economic benefits for Canada.

Amendment 5(b) deletes the Patented Medicine Prices Review Board, which is required to protect consumers, and this amendment also removes the protection for Canadian-invented medicines and thus the incentives for increased research and development in Canada.

Amendments 6, 7(a) and (b), 10(b) and (c) arise out of amendments 1(a) and (b), 2, 3, 4(a) and (b), 5(a) and (b), and are therefore inappropriate.

Amendment 9 arises out of Senate amendment 8, but is not consistent with the House amendment to Senate amendment 8, as set out below.

And, that:

Senate amendment 1(c) be amended to read as follows: "(c) Strike out lines 35 to 42 and add the following:

Patent Act

(2) For the purpose of sections 41.11 to 41.16, the notice of compliance that is first issued for either the original and distinct chemical composition of a medicine or the obvious chemical equivalent of the medicine shall be deemed to be the first notice of compliance issued in respect of that medicine."

Senate amendment 8 be amended to read as follows: "insert the heading "Transitional" and the following as clause 31:

31.(1) The Minister of Consumer and Corporate Affairs shall pay to each province for each of the fiscal years commencing in the period April 1, 1987 to March 31, 1991, for the purpose of research and development relating to medicine, an amount equal to the product obtained by multiplying

(a) the quotient obtained by dividing

(i) \$25 million by

(ii) the total population of all provinces for the fiscal year in respect of which the payment is made, by

(b) the population of the province for the fiscal year in respect of which the payment is made.

(2) Payment of any amount under this section shall be made out of the Consolidated Revenue Fund at such times and in such manner as the Governor in Council may, by regulation, prescribe.

(3) For the purposes of this section, the population of a province for a fiscal year shall be the population of that province on the first day of June of that year as determined and published by the Chief Statistician of Canada."

and the amendment of Mr. Lewis (p. 8555).

The Acting Speaker (Mr. Paproski): It being six o'clock, pursuant to Standing Order 13(5) the House will now proceed to the taking of the deferred division on the motion of Mr. Lewis for the previous question in relation to the motion of the Minister of Consumer and Corporate Affairs concerning the amendments made by the Senate to Bill C-22, an Act to amend the Patent Act and to provide for certain matters in relation thereto.

Mr. Lewis moved:

That the question be now put.

Call in the Members.

The House divided on the motion (Mr. Lewis) which was agreed to on the following division:

● (1800)

(Division No. 228)

YEAS

Members

Andre
Attewell
Bertrand
Blais
Blais-Grenier
Blenkarn
Bouchard
Bradley
Brightwell
Caldwell
Carney
Champagne
(Champlain)

Charest
Chartrand
Clark
(Brandon—Souris)
Clifford
Clinch
Coates
Collins
Cook
Cooper
Cossitt
Côté
(Lac-Saint-Jean)

Crosbie
(St. John's West)
Dantzer
Daubney
Dick
Domm
Dorin
Duguay
Epp
(Provencher)
Fennell
Ferland
Fontaine